P750 Biosimilar Infliximab Switching is Not Associated with Adverse Outcomes: A Real-World Effectiveness Analyses in a National U.S. Cohort of U.S. Military Veterans with Inflammatory Bowel Disease [PDF]
, 2023 Jason K. Hou +4 more
openalex +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Background Psoriasis is a chronic immune‐mediated inflammatory disease with a global prevalence of 2%–3% and 1.3% in Brazil. It is associated with comorbidities such as obesity, hypertension, and diabetes, all of which contribute to increased cardiovascular risk due to systemic inflammation and endothelial dysfunction.
Tiago A. S. Costa +2 more
wiley +1 more source
JEADV Clinical Practice, EarlyView.ABSTRACT Background Psoriasis is a chronic inflammatory dermatological condition associated with an elevated risk of cardiovascular events (CVEs). Systemic therapies have transformed disease management, but their cardiovascular (CV) safety profiles remain incompletely understood and inconsistently reported.
Mai Thi Hoai Son +10 more
wiley +1 more source
Open Access Rheumatology: Research and Reviews, 2017 Abuelmagd Abdalla, Niamh Byrne, Richard Conway, Thomas Walsh, Geraldine Mannion, Michael Hanly, Miriam O’Sullivan, Ann Maria Curran, John J Carey Department of Rheumatology, Galway University Hospitals, Galway ...
Abdalla A +8 more
doaj
P529. Efficacy and safety of infliximab versus adalimumab in the treatment of Crohn’s disease: The McGill Experience [PDF]
, 2016 openalex +1 more source
P705 Switching from intravenous to subcutaneous infliximab: clinical and patient experience outcomes [PDF]
, 2023 Erin Nowell +7 more
openalex +1 more source
Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy [PDF]
, 2005 Daniel Wendling +9 more
openalex +1 more source
Effect of Systemic Immunomodulators on Incidence of Alopecia Areata: A Retrospective Cohort Study
JEADV Clinical Practice, EarlyView.ABSTRACT Background Alopecia areata (AA) is a chronic autoimmune hair loss disorder. Patients with primary autoimmune diseases commonly use systemic immunomodulators to manage disease and have an increased risk of developing AA. Systemic immunomodulators have diverse immunologic effects, but their impact on AA risk is not well understood. Objectives We
Angela Rose Liu +2 more
wiley +1 more source
Treatment of Recurrent Erythema Nodosum Leprosum with Infliximab [PDF]
, 2006 William R. Faber +2 more
openalex +1 more source